Key result
Antiplatelet agents like aspirin and clopidogrel have variable and often insufficient efficacy for the secondary prevention of ischaemic non-embolic stroke.
Why the study?
Does platelet function-guided antiplatelet therapy reduce recurrent vascular events in subjects after ischaemic non-embolic stroke?
Does platelet function-guided antiplatelet therapy reduce recurrent vascular events in subjects after ischaemic non-embolic stroke?
The efficacy of standard antiplatelet agents in secondary stroke prevention is variable, highlighting a potential role for platelet function-guided therapy.
Answers are grounded in this paper and cite their sources.
Variable antiplatelet efficacy post-stroke warrants response monitoring; leaves open tailored regimens in prospective studies.
Antiplatelet agents, including aspirin and clopidogrel, remain the primary therapeutic options for secondary prevention of ischaemic non‐embolic stroke. The effectiveness of the applied therapy and the appropriate choice of agent is of key importance to subjects after stroke, contributing to minimising the risk of recurrent vascular events. However, the efficacy of antiplatelet agents is variable and in many cases definitely insufficient.
No takes yet. Share an insight, caveat, or question.
Adam Wiśniewski (2021) conducted a review in Ischaemic non-embolic stroke. Antiplatelet agents (aspirin and clopidogrel) was evaluated. Antiplatelet agents like aspirin and clopidogrel have variable and often insufficient efficacy for the secondary prevention of ischaemic non-embolic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: